All In Biotech

Drug Trial Radar · NCT00524433

Tezosentan in the Treatment of Acute Heart Failure

Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.

Last checked: Nov 20, 2026Latest source record: Jul 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 713 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

713

Actual

Start

Apr 2003

Primary completion

Jan 2005

Study completion Jan 2005

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Sep 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up period of 5 months for vital status.

Conditions

  • Acute Heart Failure
  • Acute Decompensation of Chronic Heart Failure
  • New Onset of Heart Failure

Interventions

  • tezosentanDrug

    tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of death or worsening heart failureTime frame: within 7 days following study drug initiation

Locations

42 sites in 8 countries. Site status is shown where the registry gives one.

  • Oracle Research

    Huntsville, Alabama

  • USC Medical Center

    Los Angeles, California

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • University of Miami-Jackson Memorial Hospital

    Miami, Florida

  • University Hospital

    Augusta, Georgia

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Medical Research Institute

    Slidell, Louisiana

  • Baystate Medical Center-Cardiology Section

    Springfield, Massachusetts

  • Elmhurst Hospital Center

    Elmhurst, New York

  • Columbia Presbyterian Medical Center-Heart Failure Center

    New York, New York

  • New York University School of Medicine

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • LeBauer Cardiovascular Research Foundation

    Greensboro, North Carolina

  • Baylor College of Medicine - Texas Medical Center

    Houston, Texas

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • Concord Repatriation Hospital

    Concord NSW, Australia

  • Queen Elizabeth Hospital

    Woodville SA, Australia

  • Alfred Hospital, Monash University, Central and Eastern School

    Prahran, Victoria, Australia

  • Faculty Hospital St. Anna

    Brno, Czechia

  • Krajska Nemocnice Liberec

    Liberec, Czechia

  • Klinika Kardiologie IKEM

    Prague, Czechia

  • University Hospital Vinohrady (FNKV)

    Prague, Czechia

  • Masaryk Hospital

    Ústí nad Labem, Czechia

  • Universitatsklinikum der Humboldt-Universitat Berlin, Campus Charite Mitte, Med. Klinik und Poliklinik, Kardiologie

    Berlin, Germany

  • Universitat Greifswald, Klinik fur Innere Medizin B

    Greifswald, Germany

  • Asklepios Klinik Langen, Abteilung fur Innere Medizin

    Langen, Germany

  • Universitatsklinikum Schleswig Holstein, Medizinische Klinik II, Kardiologie

    Lübeck, Germany

  • Klinik u. Poliklinik F. Inn. Med. II, Univ. Klinik Regensburg

    Regensburg, Germany

  • Jahn Ferenc, Delpesti Korhaz

    Budapest, Hungary

  • Polyclinic of the Hospitaler Brothers of St. John of God

    Budapest, Hungary

  • University of Debrecen

    Debrecen, Hungary

  • 2nd Department of Medicine & Cardiology Centre

    Szeged, Hungary

  • Cattedra di Cardiologia, c/o Spedali Civili

    Brescia, Italy

  • Istituto Clinico Humanitas, U.O. Cardiologia Clin. E Insuff. Cardiaca

    Rozzano (MI), Italy

  • Sentralsykehuset i More og Romsdal, Dept. of Cardiology

    Ålesund, Norway

  • Aker University Hospital, Div. Cardiology

    Oslo, Norway

  • Central Hospital in Rogaland, Cardiology Division

    Stavanger, Norway

  • University Department of Medicine, City Hospital

    Birmingham, United Kingdom

  • Cardiology Department, Bridlington & District Hospital

    Bridlington, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.